Would you consider exemestane (instead of fulvestrant) in post-menopausal patients with hormone receptor pos, HER2- breast cancer who progress on letrozole or anastrozole?

Generally would not. I usually do Fulvestrant +/- CDK inhibitor if not received in the first line setting, as second line and reserve exemestane to afterwards combined with everolimus. If a patient has minimal disease progression on letrozole/anastrozole and really does not want a monthly injection,...